News

Kalypsys reaps $100 million in third round

Kalypsys has raised $100 million in its third round of venture capital. Tavistock Life Sciences, one of Kalypsys' previous investors, led the round with an $89 million contribution. Previous investors Sprout Group, CMEA Ventures and KT Venture Group participated in the round. The financing increases the total private equity that Kalypsys has raised to $172 million since February 2002. Kalypsys' pipeline includes KD3010 for metabolic disorders. Other compounds in the pipeline nearing the …

Dynavax stock jumps on hep B data

Shares of Dynavax Technologies shot up 31 percent in after-hours trading after the developer announced that a late-stage trial of its experimental vaccine for hepatitis B showed that it performed better after two doses than three doses of GlaxoSmithKline's vaccine. Two doses of Hepislav protected 98 percent of volunteers compared to 25 percent protected by two doses of Glaxo's Engerix-B. Analysts say the data shows that Dynavax can successfully compete against Glaxo in the $1 billion …

Threshold delays release of glufosfamide analysis

Threshold Pharmaceuticals says it will delay a release on Phase III data for its pancreatic cancer drug glufosfamide until some time in 2007. Threshold also announced it will begin patient screening for two new mid-stage trials of glufosfamide by the end of this year for ovarian cancer and small cell lung cancer. The reason for the delay, according to a Threshold release, is that the trial will end on notification of the 258th death of one of the volunteers in the study. In its timeline …

Seradyn looks to expand following merger

The Indianapolis Star profiles Seradyn, a biotech company acquired in the recent Fisher Scientific/Thermo Electron merger. The life sciences company, which makes drug testing products, says it plans to expand its operations and hire new staff. President Mark Roberts says he plans to add 10 to 15 workers in the lab and raise the company's profile.

- here's the profile from the …

SPOTLIGHT: Novartis plans Phase III trial


Vectura is touting an announcement from Novartis that it will begin a late-stage trial of a new COPD therapy in 2007 that incorporates a drug Vectura developed. Novartis expects to ask for marketing approval of QVA149--a combinatorial therapy--in 2010. Report

C&L: Altus tapped as new ImpactRx CEO

ImpactRx has named Richard C. Altus as president and CEO.

Hemispherx Biopharma has hired Anthony A. Bonelli as president and COO.

Bioenvision has named James S. Scibetta to the post of CFO.

Adnexus Therapeutics has expanded its management team with the appointment of Bruce A. …

ALSO NOTED: Acorda gains $10M in funds; Supreme Court debates patent law; and much more...

> Acorda Therapeutics has amended its deal with Paul Capital Healthcare to gain up to $10 million in additional funds. Release

> Pain Therapeutics says its painkiller PTI-202 successfully completed a Phase I trial. Release

> The U.S. Supreme Court debated a critical test of U.S. patent law in a case that has …

Press Release: Zila Transitions to Cancer Detection Company

Press Release: Zila Transitions to Cancer Detection Company

Press Release: Auxilium Pharmaceuticals Amends Agreement with Cobra Biologics

Press Release: Auxilium Pharmaceuticals Amends Agreement with Cobra Biologics

Press Release: Pain Therapeutics Announces Positive Phase I Study Results With PTI-202

Press Release: Pain Therapeutics Announces Positive Phase I Study Results With PTI-202

Press Release: Acorda Therapeutics to Receive Up to $10 Million from Paul Capital Healthcare

Press Release: Acorda Therapeutics to Receive Up to $10 Million from Paul Capital Healthcare

Press Release: Dynavax's HEPLISAV Hep B Vaccine Shows Results In Phase 3 Trial

Press Release: Dynavax's HEPLISAV Hep B Vaccine Shows Results In Phase 3 Trial

Press Release: Threshold Pharmaceuticals Announces Guidance Change for Release of Phase 3 Trial Results

Press Release: Threshold Pharmaceuticals Announces Guidance Change for Release of Phase 3 Trial Results

Press Release: Pfizer to realign U.S. sales organization

Press Release: Pfizer to realign U.S. sales organization

Press Release: Kalypsys Raises $100 Million in a Series C Financing

Press Release: Kalypsys Raises $100 Million in a Series C Financing

Pfizer bails out on collaboration with Organon

Pfizer has decided to drop out of its collaboration with Organon to develop asenapine for schizophrenia and bipolar disease after completing a review of the compound and its place in the pharma giant's "overall portfolio." Last October researchers issued interim Phase III data that suggested they may not have enough evidence to back an NDA. Organon says it will push ahead on its own for now, and may look for another partner to complete work on the drug. In the meantime, Organon parent …

Kiadis to merge with Canada's Celmed

The Dutch biotech Kiadis and Montreal-based Celmed BioSciences say they will merge operations, both of which are focused on new oncology therapies. The merged company will operate as Kiadis Pharma with headquarters in the Netherlands and operations in Canada and Europe. Financial details were kept under wraps.

The new Kiadis Pharma "has exceptionally strong credentials in oncology with over five years of clinical patient data that allows us to further strengthen our products and …

VC: Elixir pockets $46M in third round

In the news recently for its work in the anti-aging field, Elixir Pharmaceuticals of Cambridge, MA announced it has raised $46 million in its third round of venture financing. The round includes $31 million in equity and $15 million in debt. The money will be used to support its program for Glufast, a small molecule for the treatment of Type 2 diabetes; pre-clinical activities to support an …

Cytokinetics assumes responsibility in amended pact

Shares of Cytokinetics slipped Monday after the South San Francisco-based biotech company announced that it is taking over development responsibility for two cancer therapies under an amended pact with GlaxoSmithKline. Cytokinetics took over development responsibility of SB-743921 last summer and under the revised pact will also assume responsibility for ispinesib, or SB-715992. GSK retains the option to develop the drugs at a later stage. Cytokinetics plans to focus its 2007 clinical …

Applied NeuroSolutions inks drug pact with Lilly

Applied NeuroSolutions has inked a development deal with Eli Lilly for new drugs to treat Alzheimer's. Applied NeuroSolutions gains $2 million up front along with research funds. And it stands to earn between $10 million and $20 million for each new therapy that is developed. Applied NeuroSolutions has been investigating the proteins that gather on neurons in Alzheimer's cases.

- see this release on the development …